YTTRIUM Y 90 IBRITUMOMAB TIUXETAN
drugOn this page
Also known as (90)y-ibritumomab tiuxetan90y ibritumomab tiuxetan90y-ibritumomabIbritumomab tiuxetan y-90Ibritumomab tiuxetan yttrium y-90Yttrium (90y) ibritumomab tiuxetanYttrium y-90 ibritumomab tiuxetanZevalin
Summary
Yttrium Y 90 Ibritumomab Tiuxetan (CHEMBL2108667) is an approved antibody; indicated across 17 conditions including neoplasm of mature b-cells and follicular lymphoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- Indications: 17 conditions
- Clinical trials: 48
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108667 |
| Name | YTTRIUM Y 90 IBRITUMOMAB TIUXETAN |
| Type | Antibody |
| Max phase | 4 |
Also known as: (90)y-ibritumomab tiuxetan, 90y ibritumomab tiuxetan, 90y-ibritumomab, Ibritumomab tiuxetan y-90, Ibritumomab tiuxetan yttrium y-90, Yttrium (90y) ibritumomab tiuxetan, Yttrium y 90 ibritumomab tiuxetan, Yttrium y-90 ibritumomab tiuxetan, Zevalin, YTTRIUM Y 90 IBRITUMOMAB TIUXETAN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
17 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm of mature B-cells | 4 | MONDO:0004949 | EFO:0000096 |
| follicular lymphoma | 4 | MONDO:0018906 | MONDO:0018906 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| non-Hodgkin lymphoma | 3 | MONDO:0018908 | EFO:0005952 |
| B-cell chronic lymphocytic leukemia | 2 | MONDO:0004948 | EFO:0000095 |
| Burkitt lymphoma | 2 | MONDO:0007243 | EFO:0000309 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| plasma cell myeloma | 2 | MONDO:0009693 | EFO:0001378 |
| anaplastic large cell lymphoma | 2 | MONDO:0020325 | EFO:0003032 |
| Waldenstrom macroglobulinemia | 2 | MONDO:0100280 | EFO:0009441 |
| mantle cell lymphoma | 2 | MONDO:0018876 | EFO:1001469 |
| graft versus host disease | 2 | MONDO:0013730 | MONDO:0013730 |
| Hodgkins lymphoma | 1 | MONDO:0004952 | EFO:0000183 |
| MALT lymphoma | 1 | MONDO:0007650 | EFO:0000191 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 48.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 24 |
| PHASE1/PHASE2 | 8 |
| PHASE1 | 7 |
| PHASE3 | 6 |
| Not specified | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00185393 | PHASE3 | COMPLETED | Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy |
| NCT00322218 | PHASE3 | TERMINATED | Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. |
| NCT01510184 | PHASE3 | TERMINATED | Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy |
| NCT01662102 | PHASE3 | TERMINATED | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) |
| NCT01827605 | PHASE3 | UNKNOWN | A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) |
| NCT02320292 | PHASE3 | TERMINATED | Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma |
| NCT00012298 | PHASE1/PHASE2 | TERMINATED | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
| NCT00031642 | PHASE1/PHASE2 | COMPLETED | Monoclonal Antibody Therapy in Relapsed Non-Hodgkin’s After Chemotherapy and Autologous Stem Cell Transplantation |
| NCT00048737 | PHASE1/PHASE2 | COMPLETED | Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies |
| NCT00058422 | PHASE2 | COMPLETED | Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma |
| NCT00062114 | PHASE2 | COMPLETED | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin’s Lymphoma |
| NCT00064246 | PHASE1/PHASE2 | COMPLETED | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder |
| NCT00070447 | PHASE2 | COMPLETED | Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma |
| NCT00073957 | PHASE2 | COMPLETED | Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma |
| NCT00110149 | PHASE2 | TERMINATED | Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin’s Lymphoma |
| NCT00119392 | PHASE2 | COMPLETED | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
| NCT00119730 | PHASE2 | COMPLETED | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma |
| NCT00290511 | PHASE2 | COMPLETED | Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma |
| NCT00310128 | PHASE2 | WITHDRAWN | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin’s Lymphoma |
| NCT00354822 | PHASE2 | TERMINATED | Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. |
| NCT00397800 | PHASE1/PHASE2 | UNKNOWN | Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin’s Lymphoma |
| NCT00438880 | PHASE1/PHASE2 | COMPLETED | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma |
| NCT00493454 | PHASE2 | TERMINATED | Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas |
| NCT00521560 | PHASE2 | COMPLETED | A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas |
| NCT00562978 | PHASE1/PHASE2 | COMPLETED | Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin’s Lymphoma Patients |
| NCT00577278 | PHASE2 | COMPLETED | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan |
| NCT00591630 | PHASE2 | COMPLETED | Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation |
| NCT00637832 | PHASE2 | TERMINATED | Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma |
| NCT00690560 | PHASE2 | COMPLETED | Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma |
| NCT00695409 | PHASE2 | COMPLETED | Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma |
| NCT00761384 | PHASE1/PHASE2 | COMPLETED | High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma |
| NCT00850512 | PHASE2 | COMPLETED | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy |
| NCT00902525 | PHASE2 | TERMINATED | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma |
| NCT01359592 | PHASE2 | COMPLETED | S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma |
| NCT01434472 | PHASE2 | TERMINATED | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma |
| NCT01493479 | PHASE2 | COMPLETED | Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma |
| NCT01686165 | PHASE2 | COMPLETED | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL |
| NCT01973062 | PHASE2 | TERMINATED | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma |
| NCT00033423 | PHASE1 | TERMINATED | Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
| NCT00036855 | PHASE1 | TERMINATED | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).